home / stock / myov / myov news


MYOV News and Press, Myovant Sciences Ltd. From 04/05/20

Stock Information

Company Name: Myovant Sciences Ltd.
Stock Symbol: MYOV
Market: NYSE
Website: myovant.com

Menu

MYOV MYOV Quote MYOV Short MYOV News MYOV Articles MYOV Message Board
Get MYOV Alerts

News, Short Squeeze, Breakout and More Instantly...

MYOV - Daily Insider Ratings Round Up 4/3/20

InsiderInsights' Daily Round Up articles rate the "Significance" of the Top 10 dollar value insider purchases and sales filed at the SEC on the Title date. Dollar value is only the most basic metric to assess the "Significance" of an insider transaction, however, and often not even the most im...

MYOV - Daily Insider Ratings Round Up 4/1/20

InsiderInsights' Daily Round Up articles rate the "Significance" of the Top 10 dollar value insider purchases and sales filed at the SEC on the Title date. Dollar value is only the most basic metric to assess the "Significance" of an insider transaction, however, and often not even the most i...

MYOV - Daily Insider Ratings Round-Up 3/30/20.

InsiderInsights' Daily Round-Up articles rate the "Significance" of the Top 10 dollar value insider purchases and sales filed at the SEC on the Title date. Dollar value is only the most basic metric to assess the "Significance" of an insider transaction, however, and often not even the most ...

MYOV - HAL and APA among premarket gainers

SG Blocks (NASDAQ: SGBX ) +100%  on Q4 results .. More news on: SG Blocks, Inc., EyeGate Pharmaceuticals, Inc., Kiniksa Pharmaceuticals, Ltd., Stocks on the move, , Read more ...

MYOV - Myovant Sciences inks deal for relugolix combination outside U.S.

Myovant Sciences (NYSE: MYOV ) has  entered into an exclusive license agreement with Gedeon Richter Plc., a Central Eastern Europe based pharmaceutical company where latter will commercialize relugolix combination tablet (relugolix 40 mg, estradiol 1.0 mg, and norethindrone a...

MYOV - Myovant Sciences and Gedeon Richter Enter into Exclusive License Agreement to Commercialize Relugolix Combination Tablet for Uterine Fibroids and Endometriosis in Certain Territories Outside the U.S.

Gedeon Richter to commercialize relugolix combination tablet for uterine fibroids and endometriosis in Europe, Russia - CIS, Latin America, Australia, and New Zealand Myovant to receive an upfront payment of $40 million, up to $147.5 million in regulatory and sales milestones, and t...

MYOV - Daily Insider Ratings Round Up 3/26/20

InsiderInsights' Daily Round Up articles rate the "Significance" of the Top 10 dollar value insider purchases and sales filed at the SEC on the Title date. Dollar value is only the most basic metric to assess the "Significance" of an insider transaction, however, and often not even the most i...

MYOV - Daily Insider Ratings Round-Up 3/24/20

InsiderInsights' Daily Round-Up articles rate the "Significance" of the Top 10 dollar value insider purchases and sales filed at the SEC on the Title date. Dollar value is only the most basic metric to assess the "Significance" of an insider transaction, however, and often not even the most ...

MYOV - Bristol-Myers Squibb's Multiple Myeloma Setback, And Other News: The Good, Bad And Ugly Of Biopharma

Xenon Pharmaceuticals Reports Financial Results, Misses EPS Xenon Pharmaceuticals ( XENE ) reported its fourth quarter and full-year results. While the results were largely impressive, the company missed reaching its revenue and EPS estimates. The company also provided corporate updates ab...

MYOV - Myovant Sciences Announces Cancellation of Presentation and Webcast at the Barclays Global Healthcare Conference 2020

BASEL, Switzerland, March 10, 2020 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a healthcare company focused on developing innovative treatments for women's health and prostate cancer, today announced the cancellation of its presentation and webcast at the Barclays Global Healthcare C...

Previous 10 Next 10